Pathology Analysis & Statistics, November 2014 (p20)

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Publishers

All regions

You might be interested in: Cancer, Breast Cancer, Leukemia, more »

571-620 of about 4 400 reports

Purchase Reports From Reputable Market Research Publishers

Age-related Macular Degeneration Partnering 2009-2014

Age-related Macular Degeneration Partnering 2009-2014

  • $ 695
  • Industry report
  • November 2014
  • by Currentpartnering

Age-related Macular Degeneration Partnering 2009-2014 report provides understanding and access to the age-related macular degeneration partnering deals and agreements entered into by the worlds leading ...

  • Industries : Pathology
Glaucoma Partnering 2009-2014

Glaucoma Partnering 2009-2014

  • $ 695
  • Industry report
  • November 2014
  • by Currentpartnering

Glaucoma Partnering 2009-2014 report provides understanding and access to the glaucoma partnering deals and agreements entered into by the worlds leading healthcare companies. -Trends in glaucoma partnering ...

  • Industries : Pathology
Conjunctivitis Partnering 2009-2014

Conjunctivitis Partnering 2009-2014

  • $ 695
  • Industry report
  • November 2014
  • by Currentpartnering

Conjunctivitis Partnering 2009-2014 report provides understanding and access to the conjunctivitis partnering deals and agreements entered into by the worlds leading healthcare companies. -Trends in ...

  • Industries : Pathology
Dry Eye Partnering 2009-2014

Dry Eye Partnering 2009-2014

  • $ 695
  • Industry report
  • November 2014
  • by Currentpartnering

Dry Eye Partnering 2009-2014 report provides understanding and access to the dry eye partnering deals and agreements entered into by the worlds leading healthcare companies. -Trends in dry eye partnering ...

  • Industries : Pathology
Retinopathy Partnering 2009-2014

Retinopathy Partnering 2009-2014

  • $ 695
  • Industry report
  • November 2014
  • by Currentpartnering

Retinopathy Partnering 2009-2014 report provides understanding and access to the retinopathy partnering deals and agreements entered into by the worlds leading healthcare companies. -Trends in retinopathy ...

  • Industries : Pathology
Drug Addiction Partnering 2009-2014

Drug Addiction Partnering 2009-2014

  • $ 695
  • Industry report
  • November 2014
  • by Currentpartnering

Drug Addiction Partnering 2009-2014 report provides understanding and access to the drug addiction partnering deals and agreements entered into by the worlds leading healthcare companies. -Trends in ...

  • Industries : Pathology
Angina Partnering 2009-2014

Angina Partnering 2009-2014

  • $ 695
  • Industry report
  • November 2014
  • by Currentpartnering

Angina Partnering 2009-2014 provides understanding and access to the angina partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of angina ...

  • Industries : Pathology
Acne Partnering 2009-2014

Acne Partnering 2009-2014

  • $ 695
  • Industry report
  • November 2014
  • by Currentpartnering

Acne Partnering 2009-2014 report provides understanding and access to the acne partnering deals and agreements entered into by the worlds leading healthcare companies. -Trends in acne partnering deals ...

  • Industries : Pathology
Peripheral Arterial Disease Partnering 2009-2014

Peripheral Arterial Disease Partnering 2009-2014

  • $ 695
  • Industry report
  • November 2014
  • by Currentpartnering

The Peripheral Arterial Disease Partnering 2009-2014 report provides understanding and access to the peripheral arterial disease partnering deals and agreements entered into by the worlds leading healthcare ...

  • Industries : Pathology
Learning Disability Partnering 2009-2014

Learning Disability Partnering 2009-2014

  • $ 695
  • Industry report
  • November 2014
  • by Currentpartnering

The Learning Disability Partnering 2009-2014 report provides understanding and access to the learning disability partnering deals and agreements entered into by the worlds leading healthcare companies. ...

  • Industries : Pathology
Parasitic Disease Partnering 2009-2014

Parasitic Disease Partnering 2009-2014

  • $ 695
  • Industry report
  • November 2014
  • by Currentpartnering

The Parasitic Partnering 2009-2014 provides understanding and access to the parasitic partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis ...

  • Industries : Pathology
Physician Views: Will next-generation long-acting insulins prove compelling?

Physician Views: Will next-generation long-acting insulins prove compelling?

  • $ 681
  • Industry report
  • November 2014
  • by Firstword Pharma

In the second of two diabetes-focused Physician Views polls being run by FirstWord Pharma PLUS this week (see also Physician Views: What opportunity for biosimilar basal insulin?), we are polling US and ...

  • Industries : Pathology
  • Countries : United States
Physician Views: Reaction to Bristol-Myers Squibb%s Opdivo data in non-small-cell lung cancer

Physician Views: Reaction to Bristol-Myers Squibb%s Opdivo data in non-small-cell lung cancer

  • $ 681
  • Industry report
  • November 2014
  • by Firstword Pharma

Studies of Bristol-Myers Squibb's PD-1 inhibitor nivolumab in non-small-cell lung cancer (NSCLC) have been watched closely by investors, analysts and the oncology community, given both the high level of ...

  • Industries : Pathology
Physician Views: Celgene's mongersen continues to impress in Crohn%s - is it too good to be true?

Physician Views: Celgene's mongersen continues to impress in Crohn%s - is it too good to be true?

  • $ 681
  • Industry report
  • October 2014
  • by Firstword Pharma

There are a handful of reasons why sceptics are incredulous about Celgene's mongersen, this despite - or perhaps even because of - recently unveiled Phase II results that analysts say show the oral antisense ...

  • Industries : Pathology
Physician Views: Can Movantik revolutionise the opioid-induced constipation market?

Physician Views: Can Movantik revolutionise the opioid-induced constipation market?

  • $ 681
  • Industry report
  • October 2014
  • by Firstword Pharma

It has been an eventful year for players operating in the US opioid-induced constipation (OIC) market. In June, the FDA recommended against requiring cardiovascular outcomes studies for all products within ...

  • Industries : Pathology
  • Countries : United States
Physician Views: New data for Novartis% LCZ696 set the Street abuzz, but how do cardiologists see it fitting into highly genericised heart failure market?

Physician Views: New data for Novartis% LCZ696 set the Street abuzz, but how do cardiologists see it fitting into highly genericised heart failure market?

  • $ 645
  • Industry report
  • Nov 2014
  • by Firstword Pharma

The potential blockbuster status of Novartis' LCZ696 has seemingly been cemented in the eyes of the Street thanks to solid results from the Phase III PARADIGM-HF study that were presented over the weekend. ...

  • Industries : Pathology
  • Countries : United States
Physician Views: The PD-1 inhibitor class lands - how do US oncologists expect to initially use Merck & Co.%s Keytruda?

Physician Views: The PD-1 inhibitor class lands - how do US oncologists expect to initially use Merck & Co.%s Keytruda?

  • $ 645
  • Industry report
  • September 2014
  • by Firstword Pharma

As many were expecting, approval of Merck & Co.'s pembrolizumab - now branded as Keytruda - came earlier than expected, and was confirmed on Thursday ahead of October's PDUFA date. Approved as the first ...

  • Industries : Pathology
  • Countries : United States
Brinzolamide  - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Brinzolamide - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

  • $ 653
  • Company report
  • October 2014
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that's simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension ...

  • Industries : Pathology
  • Countries : United Kingdom, Australia, Canada, Spain, Italy, France, Germany, Japan, Europe, United States, World
Duloxetine  - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Duloxetine - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

  • $ 653
  • Company report
  • October 2014
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that's simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension ...

  • Industries : Pathology
  • Countries : United Kingdom, Australia, Canada, Spain, Italy, France, Germany, Japan, Europe, United States
Sildenafil  - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Sildenafil - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

  • $ 653
  • Company report
  • October 2014
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that's simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension ...

  • Industries : Pathology
  • Countries : United Kingdom, Australia, Canada, Spain, Italy, France, Germany, Japan, Europe, United States, World
Sitagliptin  - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Sitagliptin - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

  • $ 653
  • Company report
  • October 2014
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that's simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension ...

  • Industries : Pathology
  • Countries : United Kingdom, Australia, Canada, Spain, Italy, France, Germany, Japan, Europe, United States
Temsirolimus  - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Temsirolimus - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

  • $ 653
  • Company report
  • October 2014
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that's simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension ...

  • Industries : Pathology
  • Countries : United Kingdom, Australia, Canada, Spain, Italy, France, Germany, Japan, Europe, United States, World
Donepezil  - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Donepezil - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

  • $ 653
  • Company report
  • October 2014
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that's simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension ...

  • Industries : Pathology
  • Countries : United Kingdom, Australia, Canada, Spain, Italy, France, Germany, Japan, Europe, United States, World
Irbesartan  - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Irbesartan - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

  • $ 653
  • Company report
  • October 2014
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that's simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension ...

  • Industries : Pathology
  • Countries : United Kingdom, Australia, Canada, Spain, Italy, France, Germany, Japan, Europe, United States, World
Rivastigmine  - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Rivastigmine - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

  • $ 653
  • Company report
  • October 2014
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that's simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension ...

  • Industries : Pathology
  • Countries : United Kingdom, Australia, Canada, Spain, Italy, France, Germany, Japan, Europe, United States, World
Ropinirole  - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Ropinirole - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

  • $ 653
  • Company report
  • October 2014
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that's simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension ...

  • Industries : Pathology
  • Countries : United Kingdom, Australia, Canada, Spain, Italy, France, Germany, Japan, Europe, United States, World
Valsartan  - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Valsartan - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

  • $ 653
  • Company report
  • October 2014
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that's simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension ...

  • Industries : Pathology
  • Countries : United Kingdom, Australia, Canada, Spain, Italy, France, Germany, Japan, Europe, United States, World
Dasatinib  - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Dasatinib - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

  • $ 653
  • Company report
  • October 2014
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that's simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension ...

  • Industries : Pathology
  • Countries : United Kingdom, Australia, Canada, Spain, Italy, France, Germany, Japan, Europe, United States, World
Erlotinib  - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Erlotinib - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

  • $ 653
  • Company report
  • October 2014
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that's simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension ...

  • Industries : Pathology
  • Countries : United Kingdom, Australia, Canada, Spain, Italy, France, Germany, Japan, Europe, United States, World
Gefitinib  - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Gefitinib - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

  • $ 653
  • Company report
  • October 2014
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that's simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension ...

  • Industries : Pathology
  • Countries : United Kingdom, Australia, Canada, Spain, Italy, France, Germany, Japan, Europe, United States, World
About 31 000 reports

Download Unlimited Documents from Trusted Public Sources

Pathology Description in Afghanistan

  • November 2014
    3 pages
  • Infectious Dise...  

  • Afghanistan  

    World  

    Asia  

View report >

About 200 Companies

Read our Company Profiles

Pfizer Inc.

United States

GlaxoSmithKline PLC

United Kingdom

Novartis Inc.

Switzerland

GlaxoSmithKline P.L.C.

United States

Imaging Systems L.L.C.

United States

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.